Last updated: May 25, 2026
CLEVIDIPINE suppliers and drug substance/manufacturing network: What companies supply clevidipine to pharma and hospitals?
Clevidipine (Cleviprex; IV, lipid emulsion) supply chain is dominated by the branded originator’s manufacturer plus a small number of qualified sources for critical components (clevidipine drug substance; lipid/emulsion system; manufacturing support). The market structure and procurement pattern are consistent with a narrow, tightly controlled specialty injectable supply base rather than a broad generic-style “multiple API sellers” landscape.
Which companies supply clevidipine (Cleviprex) to the US market?
Direct answer: Cleviprex is supplied commercially by The originator’s branded manufacturing organization and its distribution network. Contract or secondary sources typically supply components (lipid/excipients; sterile emulsion processing; fill-finish) rather than full, API-level “clevidipine injection” replication.
What “suppliers” usually mean for clevidipine IV emulsion
Clevidipine is not a standalone powder market like many small-molecule tablets. “Suppliers” are usually one or more of:
- Branded finished-dose manufacturer (sterile product manufacturing, fill-finish, release)
- Lipid system suppliers (neutral lipids used for the emulsion)
- Sterile manufacturing and aseptic fill-finish partners (if outsourced)
- Drug substance (clevidipine) suppliers (if outsourced upstream for drug substance)
What procurement looks like for hospitals and distributors
Hospitals typically buy clevidipine through group purchasing organizations and wholesalers. Those intermediaries do not create manufacturing capacity; they distribute whatever the branded manufacturer (or its authorized contract manufacturers) releases to market.
What suppliers make clevidipine drug substance (API) vs the finished IV emulsion?
Direct answer: Clevidipine supply typically splits into two layers:
- Clevidipine API production (chemical synthesis)
- Sterile emulsion system manufacturing and aseptic processing (formulation, sterile filtration, filling)
API layer: chemical synthesis suppliers
- API sourcing is usually concentrated and supplier changes trigger regulatory and quality updates.
- API-only substitution is uncommon for hospital procurement because the commercial supply is the finished sterile injectable.
Formulation layer: lipid emulsion system suppliers
- Clevidipine is formulated as an intravenous lipid emulsion. The “supplier set” often includes vendors for the emulsion lipids and related excipients.
- Emulsion stability and droplet-size control drive supplier qualification.
What manufacturers produce Cleviprex (clevidipine) injection?
Direct answer: The market’s practical “supplier list” for clevidipine injection is anchored on the Cleviprex branded product manufacturer and any authorized contract manufacturers involved in drug product production and fill-finish.
Why the finished-dose manufacturer matters more than API sellers
- Hospitals and wholesalers procure the final injectable.
- Manufacturing transfers, sterile processing capability, and quality control release are the limiting constraints during supply shocks.
Who supplies clevidipine excipients and lipid emulsion components?
Direct answer: The clevidipine emulsion relies on specific lipid excipients and processing inputs, with suppliers qualified for pharmaceutical-grade performance (impurity profile, stability, traceability).
Typical component categories in lipid emulsion manufacturing
- Neutral lipids used for emulsion formation
- Emulsion stabilizers/surfactants (as applicable to the labeled formulation)
- Sterile processing consumables and filtration components used under GMP aseptic methods
Are there generic clevidipine injection suppliers with FDA approval?
Direct answer: CLEVIDIPINE’s current US availability is tied to the branded injectable; generic clevidipine injection availability is not broadly comparable to common small-molecule markets. Where competition exists, it generally shows up as:
- Authorized labeling or supply equivalents through licensed partners, or
- Limited competition due to product complexity and IP/approval barriers typical for specialty sterile injectables.
What is the regulatory status of clevidipine (FDA pathway) and how does it affect supplier count?
Direct answer: The branded injectable is approved via the standard NDA route; the regulatory architecture for a complex emulsion generally keeps the supplier base narrow because applicants must demonstrate:
- Compositional sameness or clinically acceptable equivalence
- Emulsion performance attributes (droplet size distribution, stability)
- Sterility assurance and aseptic manufacturing validation
When does clevidipine lose exclusivity and open the door to additional suppliers?
Direct answer: New supplier entry is constrained by remaining patent and exclusivity (listed in Orange Book for Cleviprex) as well as manufacturing and product performance requirements for a lipid emulsion.
What to monitor for supplier entry timing
- Orange Book expiration of the composition, formulation, and method-of-use patents tied to the emulsion and use in hypertension/emergency settings
- Any paragraph IV filings (if present) that would forecast generic or biosimilar-style competitive entry
- NDA supplement changes that shift manufacturing to new contract sites
What patent landscape affects alternative clevidipine suppliers?
Direct answer: Supplier growth depends on whether alternative products can be launched without infringement or by operating under patent settlements/licensing.
Key patent types to map for clevidipine suppliers
- Composition of matter for clevidipine
- Formulation patents for lipid emulsion characteristics
- Method-of-use patents for acute hypertension/IV titration workflows
- Manufacturing process patents for emulsion preparation, droplet sizing, or sterile handling
How to evaluate clevidipine supply risk: what can cause shortages?
Direct answer: Supply risk for clevidipine tends to concentrate in:
- Limited sterile injectable capacity for the emulsion
- Limited qualified suppliers for emulsion lipids and critical GMP materials
- Regulatory friction during manufacturing transfers
- Quality holds related to emulsion performance attributes and sterility assurance
Operational “red flags” to track
- Fill-finish site changes
- GMP batch failures tied to emulsion droplet size or stability
- Vendor changes for lipid excipients that require comparability studies
Competitive landscape: branded clevidipine vs substitutes
Direct answer: Clevidipine competes clinically with other IV antihypertensives (not identical products). Those substitutes affect demand and procurement planning but do not create “API supplier” competition for clevidipine itself.
Substitutes that can reduce clevidipine purchasing demand
- Nicardipine IV
- Clevidipine-specific titration protocols vs other short-acting agents used in OR and ICU settings
(These do not change clevidipine manufacturing constraints.)
Key Takeaways
- Clevidipine supply is dominated by the branded product manufacturing network, with upstream suppliers usually limited to qualified lipid/excipient and sterile manufacturing inputs rather than a broad open API marketplace.
- The practical supplier “list” for clevidipine is narrow because the product is a sterile lipid emulsion, which constrains manufacturing transfer, quality release, and component qualification.
- Competitive entry depends on Orange Book patent/exclusivity status and any patent challenges or licensing structures, not on generic market dynamics typical of tablets.
FAQs
1) Who is the main clevidipine injection supplier in the US?
The primary supplier is the Cleviprex branded manufacturer and its authorized distribution network that releases the finished sterile emulsion.
2) Can hospitals source clevidipine from API distributors directly?
No. Hospitals procure the finished sterile injectable through wholesalers/GPO channels, not API-only supply.
3) What determines clevidipine emulsion supply availability?
Sterile injectable manufacturing capacity, emulsion performance control (droplet size/stability), and qualification of GMP lipid/excipient inputs.
4) What patent types block generic clevidipine injection entry?
Composition, formulation/emulsion characteristics, and method-of-use patents listed for Cleviprex in the Orange Book, plus any process/manufacturing patents tied to emulsion preparation and quality attributes.
5) What is the most common cause of clevidipine shortages?
Supply constraints linked to sterile emulsion manufacturing disruptions or quality holds affecting emulsion attributes and sterility assurance.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- FDA. Drug Approval Reports and labeling information for Cleviprex (clevidipine). U.S. Food and Drug Administration.
